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Introduction
Disorders of sex development (DSD) are defined as 
congenital conditions in which development of 
chromosomal, gonadal, or anatomical sex is atypical (1). In
2006, the Lawson Wilkins Pediatric Endocrine Society
(LWPES) and the European Society for Paediatric
Endocrinology (ESPE) published a consensus statement on
management of intersex disorders and proposed the
umbrella term ‘DSD’ instead of terms like ‘intersex’,
pseudohermaphroditism (PH)’, ‘hermaphroditism’, ‘sex
reversal’, which are often perceived as pejorative by
patients and can be confusing to both health professionals
and parents (2,3). Besides the new nomenclature, these
two societies proposed a new classification system for
causes of DSDs on the basis of karyotype analysis. The 
new DSD classification includes three main diagnostic 
categories: sex chromosome DSD, 46,XY DSD (formerly
male PH) and 46,XX DSD (formerly female PH). The 
category of sex chromosome DSD embraces not only
ovotesticular DSD (formerly true hermaphroditism) and
45,X/46,XY mixed gonadal dysgenesis, but also Turner’s
syndrome (TS) and Klinefelter’s syndrome (KS), which are
not included in the previous classifications of intersex 
disorders (4,5). Because the LWPES/ESPE consensus has
taken the karyotype as the primary root, ovotesticular DSD
has been classified in three DSD categories - XX, XY and
XX/XY.  The new classification also includes disorders 
such as vanishing testes syndrome and TS, which are not
associated with genital ambiguity at birth. Thus, it would be
ABSTRACT
Objective: In 2006, the Lawson Wilkins Pediatric Endocrine Society
(LWPES) and the European Society for Paediatric Endocrinology (ESPE)
published a consensus statement on management of intersex disorders.
The aim of our study was to determine the etiological distribution of 
disorders of sex development (DSD) according to the new DSD 
classification system and to evaluate the clinical features of DSDs in our
patient cohort.   
Methods:We retrospectively reviewed the records of patients followed
up during the past three years. The subjects were divided into three 
etiologic groups according to their karyotypes. The definite diagnoses
in each subgroup were established by clinical and laboratory 
investigations including abdominopelvic imaging as well as basal and
stimulated hormone measurements. Molecular genetic testing, except
for CYP21A2 gene, could not be performed. 
Results: Out of a total of 95 patients, 26 had sex chromosome DSD, 45
had 46,XY DSD and 24 had 46,XX DSD. The most common causes of
DSDs were Turner’s syndrome (TS), congenital adrenal hyperplasia
(CAH) and androgen insensitivity syndrome (AIS). There was a 
wide variation in age of presentation ranging from 1 day to 17.5 years
with a mean of 6.5±6.5 years. The most frequent complaints at 
presentation were ambiguous genitalia, isolated perineal hypospadias
and short stature. 
Conclusion: The results of our study demonstrate that the new 
DSD classification system leads to a major change in the distribution of
etiological diagnoses of DSDs, which is exemplified by the significant
frequencies of TS and vanishing testes syndrome. This alteration
expands the clinical spectrum and increases the mean age at diagnosis.
However, the most common causes of ambiguous genitalia, such 
as CAH and AIS, remain unchanged. Further studies using molecular
genetic analyses are needed to give a more precise distribution of 
etiologies of DSDs, especially in 46,XY patients.
Key words: Disorders of sex development, etiology, classification, 
children, adolescents
C Co on nf fl li ic ct t   o of f   i in nt te er re es st t: : None declared
R Re ec ce ei iv ve ed d: : 22.12.2010 A Ac cc ce ep pt te ed d: : 02.03.2011expected that the inclusion of such entities into the new
classification might lead to changes in the distribution of 
etiological diagnoses.
There are many studies on intersex disorders, 
whereas, to our knowledge, there are no data on the 
frequency of etiological diagnoses based on the new DSD
classification system proposed by the LWPES/ESPE 
consensus group. Therefore, the aim of our study was to
determine the etiological distribution of DSDs according to
the new classification and to evaluate the clinical features
of the most commonly encountered DSDs in our patient
cohort.
Methods
We retrospectively reviewed the records of patients
with DSD followed up during the past three years at the
Department of Pediatric Endocrinology of Ondokuz May›s
University. A detailed history including age at presentation,
main complaints, sex of rearing, consanguinity, and 
family history of similar illness was taken for each patient.
A thorough clinical examination consisting of anthropometry,
assessment of pubertal stage, and presence of 
hyperpigmentation, hypertension, associated anomalies or
dysmorphic features was made and recorded for each
patient. Prader scoring system and external masculinization
score (EMS) were used to determine the degree of 
external virilization in 46,XX and 46,XY DSD patients  (6,7).
Criteria suggesting DSD included overt genital ambiguity,
apparent female genitalia with clitoromegaly, posterior 
labial fusion or inguinal/labial mass, and apparent male 
genitalia with non-palpable testes, micropenis, isolated 
perineal hypospadias or mild hypospadias with undescended
testis (2). Also, file records of older children and 
adolescents who had incomplete or delayed puberty or 
primary amenorrhea were retrospectively evaluated with
respect to DSD. Our study also comprised patients with
diagnoses such as TS and KS, which are included in the
new DSD classification. Patients with non-congenital
(acquired) problems of late puberty were excluded from this
study.   
As a part of routine evaluation of DSD, we performed 
karyotype analysis, abdominopelvic ultrasound (if 
required, magnetic resonance imaging), and hormone 
measurements including cortisol, 11-deoxycortisol (11-DOC),
17-hydroxyprogesterone (17-OHP), dehydroepiandrosterone
sulfate (DHEA-S), androstenedione (A), testosterone (T), 
dihydrotestosterone (DHT), estradiol (E2) and gonadotropins.
When it was necessary to demonstrate the presence or
absence of functioning testicular tissue, as in the case of
patients with suspected ovotesticular DSD and testicular
dysgenesis or anorchia, the levels of anti-Müllerian 
hormone (AMH) and inhibin B were measured. We routinely
analyze the common mutations in the CYP21A2 gene in
congenital adrenal hyperplasia (CAH) patients. However,
molecular genetic testing for mutations in androgen 
receptor (AR) gene and 5α-reductase gene in patients with
defects in androgen action could not be performed. 
Sex steroids (T and E2) and gonadotropins were 
measured by immunochemiluminescence metric assay
(ICMA) using Abbott commercial kits. Adrenal steroids and
DHT were measured by radioimmunoassay (RIA), AMH and
inhibin B - by enzyme-linked immunosorbent assay (ELISA)
using DSL kits.
The patients with DSD were divided into three etiologic
groups according to their karyotypes: sex chromosome
DSD, 46,XY DSD and 46,XX DSD. Sex chromosome DSDs
were subdivided into four diagnostic categories according
to karyotype: 45,X (TS and variants), 47,XXY (KS),
45,X/46,XY (mixed gonadal dysgenesis) and 46,XX/46,XY
(chimerism, ovotesticular DSD).
In the 46,XY DSD patient group, human chorionic
gonadotropin (hCG) stimulation test was carried out by
administering 1 000 to 1 500 units of hCG daily IM for three
consecutive days to determine the ability of the gonads to
produce T and DHT. An increment in plasma T (Δ T) of more
than 0.8 ng/mL or an absolute level greater than 0.9 ng/mL
after hCG treatment was considered to be indicative of the
presence of functioning testicular tissue and was defined
as normal (8); T-to-DHT ratio greater than 30 was accepted
as suggestive of 5α-reductase deficiency (9); T-to-A 
ratio smaller than 0.8 was accepted as suggestive of 
17β-hydroxysteroid dehydrogenase (17β-HSD) deficiency
(9).  In patients with micropenis without overt ambiguous
genitalia, congenital hypogonadotropic hypogonadism was
investigated by testing basal and GnRH-stimulated
gonadotropin levels.
Vanishing testes syndrome was defined as normal 
virilized external genitalia, no testosterone response to
hCG, and bilateral anorchia detected by imaging studies.
Androgen insensitivity syndrome (AIS) was diagnosed in
undervirilized males who had normal T and DHT response
to hCG stimulation and absence of Müllerian structures.
Those with normal female external genitalia were 
considered as complete AIS (CAIS) and the rest - as partial
AIS (PAIS). Persistent Müllerian duct syndrome (PMDS)
was defined as normal male external genitalia, normal
response to hCG, and presence of Müllerian structures
detected by ultrasound.  
In the 46,XX DSD group, the virilized females were 
first assessed with respect to basal (and when indicated,
ACTH-stimulated) levels of adrenal steroids and androgens.
Patients with elevated serum levels of 17-OHP and T 
were diagnosed as CAH. The diagnosis of CAH due to 
21-hydroxylase deficiency was established by a serum 
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the first 48 hours and was confirmed by CYP21A2 gene
analysis. Patients with markedly elevated serum levels of
11-DOC and DHEA-S together with moderately increased
serum 17-OHP levels were accepted as 11β-hydroxylase
and 3β-hydroxysteroid dehydrogenase deficiencies, 
respectively. Virilized females with normal 17-OHP and T
levels were categorized as maternal androgen excess (such
as luteoma) or congenital structural abnormality. In these
cases, to exclude ovotesticular DSD, serum levels of AMH
and inhibin B were measured, and imaging of the internal
genitalia and gonads was performed. Gonadal (ovarian) 
dysgenesis was diagnosed in 46,XX DSD patients who 
presented with absent breast development or primary
amenorrhea, high gonadotropin levels, and streak 
(underdeveloped) gonads detected by imaging studies.
The data were analyzed using SPSS software (Statistical
Package for the Social Sciences, version 15; SPSS Inc.,
Chicago, IL, USA). The results are given as mean±SD 
or median (range) values, and as percentages, where 
appropriate. Comparison between PAIS patients reared as
male and those raised as female regarding EMS was made
using the Mann-Whitney U test. A p value of less than 0.05
was considered statistically significant.
Results
A total of 95 patients met the criteria for DSD. There
was a wide variation in age at presentation ranging from 1
day to 17.5 years with a mean age of 6.5±6.5 years. Thirty
eight patients presented in infancy, 22 - between 1 and 10
years, and 35 - at ages older than 10 years (Figure 1). A 
history of consanguinity was obtained in 17 cases (18%).
The consanguinity rate in CAH patients (43%) was 
higher than that in the entire study group. At the time of
presentation, while 37 patients - newborns and young
infants - were not yet assigned a sex of rearing, in the older
age groups, 22 patients were raised as males and 36 as
females. A total of 9 patients with a 46,XY karyotype 
(5 - PAIS, 3 – CAIS, and 1 - 5α-reductase deficiency) had
been reared as females, and 2 CAH patients with 46,XX
karyotype as males. All patients in the series were assigned
female or male sex by a gender assessment team 
composed of pediatric specialists in endocrinology, surgery,
urology and psychiatry as well as medical geneticist. After
gender (re)assignments, the total study group contained 42
males and 53 females. The main complaints at presentation
in DSD patients were ambiguous genitalia (n=23), short
stature (n=19), isolated perineal hypospadias (n=9), primary
amenorrhea (n=8), late or incomplete puberty (n=8),
micropenis (n=6) and clitoromegaly (n=5).
Out of a total of 95 patients, 26 had sex chromosome
DSD, 45 had 46,XY DSD and 24 had 46,XX DSD (Table 1).
TS (n=21) was the most common cause (80%) of sex 
chromosome DSD. There were a few patients with sex
chromosome DSD other than TS, i.e. 45,X/46,XY mixed
gonadal dysgenesis (n=3), 45,XX/46,XY ovotesticular DSD
(n=1) and 47,XXY, KS (n=1). Patients with mixed gonadal
dysgenesis had overt ambiguous genitalia together with a
normal testis on one side and a streak (dysgenetic) gonad
on the contralateral side. These patients were assigned
male sex and their dysgenetic gonads were removed.
Histological examination did not reveal any sign of germ cell
malignancies. A patient presenting with genital ambiguity
had Müllerian structures and bilateral ovotesticular gonads
on histological examination. Bilateral gonadectomy was
performed in a 46,XX/46,XY DSD patient who had 
been reared and assigned as female.  Gonadoblastoma or
germinoma were not detected in the removed gonads.  The
patient with KS presented with delayed puberty.
Fifty three percent of patients with TS  had 45,X 
karyotype, and the remaining had various karyotype 
abnormalities such as mosaicism (45,X/46,XX;14%),
isochromosome (45,X,i(Xq); 10%) and ring X chromosome
(46,X,r(X); 5%). The mean age at diagnosis for TS patients
was 12.1±4.9 years (from intrauterine period to 17.5 years).
Of 21 patients with TS, 16 (76%) had presented at ages
older than 10 years with main complaints of short stature
and primary amenorrhea (Figure 1). Three patients, of ages
between 1 and 10 years, presented with short stature. One
patient was diagnosed in the newborn period with 
lymphoedema of the feet, and another one - incidentally at
amniocentesis. The mean height SD score of the TS
patients was -3.82±0.75. Pelvic ultrasound revealed small
or no ovarian tissue in all TS patients. Plasma levels of 
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Figure 1. The age distribution of DSD patients according to their 
etiologic diagnoses
The most frequent diagnoses of the 95 patients with disorders of sex 
development (DSD) were Turner’s syndrome (TS, n=21) congenital adrenal
hyperplasia (CAH, n=16) and partial androgen insensitivity syndrome (PAIS,
n=14). While TS patients were mostly diagnosed in adolescence, patients 
with salt-wasting and simple virilizing CAH were usually seen at infancy and
childhood, respectively. PAIS and other DSD patients were observed in all age
groups, with a predominance in infancy
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40
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Others
TS
CAH
PAISfollicle-stimulating hormone, luteinizing hormone and E2
were 97.3±41.9 (24-170) mIU/mL, 19.7±10.7 (0.15-44)
mIU/mL and 11.9±4.4 (5.3-21) pg/mL, respectively. 
Defects in androgen action [AIS (14 partial, 3 complete)
and 5α-reductase deficiency (n=3)] constituted the largest
fraction (44%) of the 46,XY DSD group. Isolated perineal
hypospadias (n=9), vanishing testes syndrome (n=6),
micropenis with mild hypospadias or cryptorchidism (n=6)
and PMDS (n=2) were among other diseases in this group
(Table 1). Two patients’ genital ambiguity was associated
with unidentified syndromes. In our study group, there was
no case with 46,XY gonadal dysgenesis or T biosynthesis
defect.
The mean age at diagnosis for PAIS patients was
5.7±5.9 years (1 day-15.4 years). The ages at presentation
were under one year in 6 patients, between 1 and 10 years
in 3 patients, and above 10 years in 5 patients (Figure 1). In
both infancy and childhood, the main complaint at 
presentation was overt genital ambiguity. However, 
adolescent patients with PAIS presented with 
clitoromegaly, amenorrhea, and incomplete puberty and
had already been reared as females. In addition, three CAIS
patients raised as females had presented with incomplete
puberty or primary amenorrhea after 10 years of age. Signs
related to some androgenic effects, such as pubic/axillary
hair and phallic enlargement, differentiated the females
with PAIS from those with CAIS. Breast development and
amenorrhea were seen as common clinical features in both
patient groups. Median value of EMSs  was 7 (range: 2-10;
normal: 0-12) in all PAIS patients. The median EMS 
(8.5; range: 4-10) for PAIS patients reared as male was 
significantly higher than that (3; range: 2-5) for PAIS patients
raised as female (p<0.001). These scores in patients with
CAIS ranged from 1 to 2, representing the presence of
abdominal or inguinal testicles with normal female external
genitalia (7). In the entire AIS group, plasma levels of basal
and hCG-stimulated T were 1.17±1.60 (0.08-5.90) ng/mL
and 4.88±2.91 (0.54-12.5) ng/mL, respectively. In all
patients with AIS except two, serum peak T levels 
were higher than 1 ng/mL. In two patients whose 
hCG-stimulated T levels were 0.54 and 0.85 ng/mL, the T/A
ratios were 2.6 and 3.2, respectively. These values were
not considered as suggestive of 17β-HSD deficiency. Also,
these patients were not considered as gonadal dysgenesis
because of normal age-matched serum AMH and inhibin B
levels and normal-appearing testes by imaging studies. On
the other hand, these two patients were older children who
had undescended testes; thus, incomplete responses to
hCG might have been a result of Leydig cell dysfunction
secondary to cryptorchidism. After hCG stimulation, the
mean T/DHT ratio was 10.1±8.2 (2.5-29.1) in the PAIS/CAIS
groups. In three patients accepted as 5α-reductase 
deficiency, these ratios were 36.3, 54.6 and 66.5. In 
addition, serum levels of hCG-stimulated T and T/DHT ratios
were normal in the other 46,XY DSD patients who had 
isolated perineal hypospadias (n=9) and micropenis 
associated with mild glandular hypospadias or 
cryptorchidism (n=6). In 46,XY DSD group, there was no
patient with congenital hypogonadotropic hypogonadism.
The majority of patients with 46,XX DSD had CAH, 
consisting of 21-hydroxylase (n=14), 11β-hydroxylase (n=1)
and 3β-hydroxysteroid dehydrogenase (n=1) deficiencies.
Four patients presenting with delayed puberty or primary
amenorrhea were diagnosed as 46,XX gonadal dysgenesis.
In the other four mildly virilized newborn females who 
had isolated clitoromegaly (n=2) or clitoromegaly with 
partial labial fusion (n=2), serum hormone measurements
(including 17-OHP, DHEA-S, T, androstenodione, AMH 
and inhibin B) were in normal ranges, and abdominopelvic
imaging also revealed normal internal genitalia and gonads.
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Table 1. Etiological classification in 95 patients with DSD
Main category Etiologic diagnosis N
Sex chromosome  45, X Turner’s syndrome and variants 21
DSD (n=26) 45,X/46,XY Mixed gonadal dysgenesis  3
46,XX/46,XY Ovotesticular DSD 1
47, XXY Klinefelter’s syndrome 1
46, XY DSD  Defects in androgen action 20
(n=45) Partial androgen insensitivity syndrome 14
Complete androgen insensitivity syndrome 3
5α-reductase deficiency 3
Isolated perineal hypospadias 9
Vanishing testes syndrome  6
Micropenis† 6
Persistent Müllerian duct syndrome 2
Syndromic associations 2
46, XX DSD  Congenital adrenal hyperplasia (CAH) 16
(n=24) Ovarian dysgenesis 4
Congenital structural abnormalities* 3
Maternal androgen excess  1
DSD: disorders of sex development
†These patients had micropenis with mild glandular hypospadias (n=4) or 
cryptorchidism (n=2).
*These patients had isolated clitoromegaly (n=2) or clitoromegaly with labial 
adhesion (n=1)In this group, there was no history of maternal drug intake
during pregnancy; however, one mother had experienced
temporary excessive hair growth and developed acne 
during the first trimester. The reason of androgenic effect in
these patients could not been completely understood. In a
patient whose mother had been mildly androgenized 
during pregnancy, the probable cause of virilization was
considered to be a luteoma. The other three patients were
categorized as congenital structural abnormality and were
followed up (Table 1). 
Out of 14 females with CAH due to 21-hydroxylase 
deficiency, 9 had salt-wasting type and 5 had simple 
virilizing type.  The median age at diagnosis for salt wasters
was 5 (1-25) days. Patients with simple virilizing CAH 
presented at median age of 5.3 (1.6-13.1) years with 
previously unrecognized genital ambiguity and/or virilization.
Two patients from the latter group had been reared as male
sex. The oldest one had heterosexual pseudopuberty and
short stature. Hyperpigmentation was detected in six
patients. Median value of Prader scores for patients with
21-hydroxylase deficiency was 4 (range: 3-5). Plasma levels
of 17-OHP and T at diagnosis were 427±332 (227-1200)
ng/mL and 6.4±5.9 (0.8-16) ng/mL, respectively. A patient
with 11β-OH deficiency had presented at 5.5 years of age
with unrecognized genital ambiguity (Prader 3 virilization),
pubic hair and hypertension. Serum levels of 17-OHP, 
T and 11-DOC were 54 ng/mL, 1.1 ng/mL and >25 ng/mL,
respectively. A female patient presenting with salt wasting
and mild clitoromegaly (Prader 2 virilization) at 3 months of
age was diagnosed with CAH due to 3β-hydroxysteroid
dehydrogenase  deficiency because of increased serum 
levels of DHEA-S (673 μg/dL), 17-OHP (25 ng/mL) and T
(0.87 ng/mL).
Discussion
In 2006, the LWPES and the ESPE published a 
consensus statement on the management of ‘intersex’ 
disorders and proposed a new classification for DSD (2,3).
To our knowledge, to date, there is no study regarding the
etiological classification of DSDs according to the new 
consensus document. Therefore, this is the first study 
evaluating the etiological diagnoses of DSDs according to
the new classification, and we believe it provides some
interesting data.
Firstly, our data demonstrate that the most common
causes of DSDs were TS, CAH and PAIS and, that patients
with DSD may present at a wide age range varying from the
first day of life to late adolescence. Our results also indicate
that the clinical manifestations of DSDs are not limited to
ambiguous genitalia, but show a broad spectrum including
isolated hypospadias, micropenis, clitoromegaly, 
incomplete puberty, amenorrhea and, even, short stature. It
is well known that PAIS and CAH are ‘intersex’ disorders
associated with genital ambiguity, whereas TS and 46,XX
gonadal dysgenesis are not. The results of our 
study demonstrate that the inclusion of TS and ovarian 
dysgenesis into the new etiologic classification of DSD has
been the main factor that expands the clinical spectrum and
increases the average age at diagnosis.
The generic term DSD was proposed and defined 
as congenital conditions in which development of 
chromosomal, gonadal or anatomical sex is atypical (1,2,3).
This nomenclature, which is recommended instead of the
word ‘intersex’ referring primarily to external genital 
ambiguity, may be confusing in the clinical evaluation of
patients. TS, the most frequent diagnosis in our DSD
cohort, is a condition in which both chromosomal and
gonadal sex are abnormal despite normal female external
genitalia. Girls with TS are usually diagnosed in late 
childhood or adolescence when they are investigated for
short stature or delayed puberty. Evaluation of patients with
only ambiguous genitalia for DSD may cause some DSD
patients to be overlooked.  Therefore, our study indicates
that a number of subjects with short stature and late 
puberty, who especially have some dysmorphic features
consistent with TS, possibly will be identified as DSD
patients.
TS is one of the most common sex chromosome 
abnormalities with an incidence of 1:2000 to 1: 5000 in 
live-born females (10). Thus, it appears reasonable that in
this cohort, TS also constitutes a significant proportion of
DSD cases. In addition, it is noteworthy that we have found
only one patient with KS in our DSD cohort. The number of
patients with KS as compared to those with TS is very low,
given its reported incidence ranging between 1:500 and
1:1000 live births (11). However, while girls with TS usually
present with short stature in the prepubertal period or with
primary amenorrhea at puberty, the diagnosis of KS is rarely
made before puberty because of paucity or subtleness 
of clinical manifestations in childhood. It is likely that a 
significant proportion of children with mosaic forms of KS or
with milder phenotypes may not have been diagnosed in
the age group covered in this study.   
Approximately fifty percent of the patients in the 
cohort had 46,XY DSD. This finding is consistent with other
studies (12,13,14). The most common cause of 46,XY DSD
was AIS, either PAIS or CAIS, representing 44% of 46,XY
patients.  The percentage of PAIS patients in our DSD
cohort is moderately higher than the results of previous
studies (12,13,14), which can be partly attributed to the 
fact that we have used a T/DHT ratio as high as 30 to 
differentiate 5α-reductase deficiency from AIS. A few
patients who had a value less than 30 might have had 
5α-reductase deficiency. In addition, our 46,XY DSD group
included patients with isolated perineal hypospadias 
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these patients, we ruled out a probability of Leydig cell 
dysfunction. Such subjects may have been either cases of
isolated anatomical defect of unknown etiology or may 
represent the milder end of the spectrum of PAIS (9).
Therefore, in the 46,XY DSD patients who have normal T
production, diagnoses of AIS and 5α-reductase deficiency
need to be confirmed by molecular genetic analyses. 
On the other hand, the identification of a causative AR
mutation in PAIS population is rare (12). In fact, it is 
possible that patients with CAIS or PAIS in whom no 
mutations  were found in the AR gene may carry a mutant
coactivator protein to explain the androgen resistance (9).
Even though one of the major limitations encountered in
our study is the inability to make definite etiological 
diagnoses for 46,XY DSD patients, it is true that 
undermasculinized patients with normal androgen production
(demonstrated by hCG stimulation) have been exposed 
to insufficient androgen effects, regardless of the cause
(failure to produce DHT or failure to respond to androgens).
Therefore, the findings of this study suggest that 46,XY
DSD mostly results from defects in androgen action and
that androgen biosynthesis defects are rarely seen.
However, we have to emphasize that we have not done
genetic analysis in the presumed AIS cases.  
Interestingly, we observed that the frequency of 
vanishing testes syndrome among 46,XY DSD patients was
notably high. These patients presenting with undescended
testes had no genital ambiguity. Because vanishing testes
syndrome was not in the former etiological classifications
of intersex disorders (4,5), its frequency within DSD is
unknown. Cryptorchidism, together with hypospadias, is
among the most common genitourinary anomalies in male
children, affecting 1.6% to 9% live births (15). In a recent
study, the prevalence of cryptorchidism at birth was 
found to be 5.9%, and approximately one fourth of 
the patients had non-palpable testes (16). Another new 
population-based study carried out in boys aged less than
one year to 19 years has established that the prevalence of
cryptorchidism was 1.52% (17). A very recent study has
shown that about half of the patients with impalpable
testes had vanishing testes syndrome (18). Therefore, 
we consider that the finding of remarkable frequency of
vanishing testes syndrome in the new DSD classification
system is not unexpected.
In the 46,XX DSD group, the most common condition
was CAH due to 21-hydroxylase deficiency, a finding 
compatible with its worldwide incidence of 1:14 000 live
births (19). While CAH was identified to occupy second
place in terms of frequency following TS, it was the most
common etiology in patients presenting with genital 
ambiguity. In fact, CAH is the commonest cause of 
ambiguous genitalia of the newborn (20). In an epidemiological
study, the incidence of ambiguous genitalia in neonates
was identified as 1:5 000 births, and the most common
diagnosis was CAH, followed by AIS and mixed gonadal
dysgenesis (21). Our results are in agreement with this
study and suggest that CAH remains the most 
common cause of ambiguous genitalia, regardless of the
classification system used in DSD.
In conclusion, this study reveals that the new DSD 
classification system leads to a major change in the 
distribution of etiological diagnoses of DSDs, which 
is exemplified by the significant frequencies of TS and 
vanishing testes syndrome. However, the most common
causes of ambiguous genitalia such as CAH and AIS remain
unchanged. Further studies using molecular genetic 
analyses are needed to give a more precise distribution of
etiologies of DSDs, especially in 46,XY patients.
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